AZ bags positive results in investigational Lupus drug trial
The drug achieved a statistically-significant and clinically-meaningful reduction in disease activity.
Read More
Tag: anifrolumab
AZ’ lupus therapy fails to hit the mark
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
